Evidence map›Paper›PMID 26363909›Full record

ArticleDrugs & aging2015

Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study.

Abhishek S Chitnis, Rajender R Aparasu, Hua Chen, Mark E Kunik, Paul E Schulz, Michael L Johnson

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs & aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Abhishek S ChitnisRetrospective Observational Studies, Evidera, Lexington, MA, USA.
Rajender R AparasuDepartment of Pharmaceutical Health Outcomes and Policy, Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, 1441 Moursund Street, Houston, TX, 77030, USA.
Hua ChenDepartment of Pharmaceutical Health Outcomes and Policy, Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, 1441 Moursund Street, Houston, TX, 77030, USA.
Mark E KunikHouston VA Health Services Research and Development, Center for Innovations in Quality, Effectiveness and Safety, and Development Center of Excellence, Houston, TX, USA.
Paul E SchulzThe University of Texas Health Science Center at Houston, Department of Neurology, Neurocognitive Disorders Center, Houston, TX, USA.
Michael L JohnsonDepartment of Pharmaceutical Health Outcomes and Policy, Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, 1441 Moursund Street, Houston, TX, 77030, USA. mikejohnson@uh.edu.
University of Houston · USHealth Services Research & Development · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHeart failure (HF) is associated with an increased risk of dementia, and studies show that dyslipidemia may be involved in the pathogenesis of dementia. However, it is unclear whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are associated with a lower risk of dementia in HF patients. The present study examines the effectiveness of statins to prevent dementia in HF patients.

methodsThis retrospective longitudinal study used a cohort of patients with HF identified from a local US Medicare Advantage Prescription Drug plan to examine the incidence of dementia with up to 3 years of follow-up. A multivariable time-dependent Cox model and inverse-probability-of-treatment weighting (IPTW) of the marginal structural model were used to estimate the risk of developing dementia. Adjusted dementia rate ratios were estimated among current and former statin users, as compared with nonusers.

resultsThe study included a total of 8062 HF patients (mean age 74.47 ± 9.21 years), of whom 1135 (14.08%) were diagnosed with dementia during a median follow-up of 22 months. Using the time-dependent Cox model, the adjusted dementia rate ratios among current and former users were 0.93 (95% confidence interval [CI] 0.71-1.21) and 0.99 (95% CI 0.79-1.25), respectively. Use of IPTW resulted in similar findings of 1.24 (95% conservative CI 0.89-1.72) among current users and 0.94 (95% conservative CI 0.67-1.31) among former users as compared with nonusers.

conclusionThis study found no difference in the risk of dementia among current and former users of statins as compared with nonusers in an already at-risk HF population.

Indexed as

AgedAged, 80 and overCohort StudiesDementiaDyslipidemiasFemaleHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceLongitudinal StudiesMaleMiddle AgedRetrospective StudiesRiskHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID26363909
OpenAlexW1933061886

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.